Vir Biotechnology shares skyrocketed on Monday following a $335 million licensing agreement, while Diamondback Energy and Whirlpool faced after-hours declines amid falling oil prices and debt restructuring efforts.
Biotech Breakthroughs and Energy Volatility
Vir Biotechnology emerged as the session's top performer, with its stock price climbing 62% to $12.07. The rally followed the announcement of a $335 million licensing agreement for its prostate cancer treatment, a move that significantly bolsters the firm's oncology pipeline and investor sentiment.
Conversely, Diamondback Energy reported a loss as falling oil prices dented the valuation of its 2025 acquisitions. The energy producer’s shares fell 3% to $169.50 in after-hours trading as investors reacted to the impact of commodity price swings on the company's recent expansion strategy.
Debt Management and Growth Forecasts
Whirlpool shares slipped 7.5% to $76.97 after the company initiated public offerings to address its debt obligations. According to the company, the capital raise is also intended to fund ongoing investments in automation technology to streamline its manufacturing operations.
Telehealth provider Hims & Hers Health also saw a retreat, with shares dropping 6.6% to $14.48. The decline followed a company report guiding for first-quarter revenue that fell short of analyst expectations, raising concerns about the pace of growth in the direct-to-consumer healthcare market.
Comments (0)
No comments yet. Be the first!